BofA lowered the firm’s price target on AMN Healthcare (AMN) to $26 from $30 and keeps an Underperform rating on the shares. Q4 EBITDA beat expectations, but the next quarter’s core guidance is “well below expectations,” says the analyst, who cut the firm’s 2025 and 2026 EBITDA estimates to reflect the lower run-rate.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare price target lowered to $40 from $47 at Truist
- Cautious Outlook on AMN Healthcare Services Amid Lower Guidance and Contract Labor Challenges
- AMN Healthcare Reports 2024 Financial Results and Outlook
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- AMN Healthcare sees Q1 revenue $660M – $680M , consensus $657.8M
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue